What genetic tests from 23andMe, Veritas and Genos really told me about my health
By Tina Hesman Saey,
ScienceNews
| 05. 22. 2018
Direct-to-consumer genetic testing first came on the market about a decade ago, but I resisted the temptation to see what health information is hidden in my DNA — until now.
As a molecular biology writer, I’ve been skeptical that the field of genetics is mature enough to accurately predict health (see related article). What finally motivated me to send away my DNA in the mail was the fact that companies are now offering much more genetic information. Is more better? Would an expensive test that deciphered my entire genetic instruction manual, or genome, reveal more about me than more limited tests? That’s what I wanted to find out.
For health testing, I sent spit samples to 23andMe, Genos and Veritas Genetics, three companies that represent the various levels of DNA testing available to consumers. (I did ancestry testing, too; you can read about my experiences with that in June.) These companies all analyze natural spelling variations in the string of letters that make up DNA. Where most people have, say, a “G,” some might have an “A.”...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...
